Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTenaya Therapeutics Inc

Tenaya Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.36015 USD 0.04 ( 13.97%)
Last update at 2026-11-06T21:00:00Z
VOLUME
2865661
Market Cap
361.18M

Momentum Score

…

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.33
Low
0.36
High
52 Week Price Range
1.66
Low
8.09
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Tenaya Therapeutics is a clinical-stage biotechnology company developing gene-regulatory therapies to address heart failure and other cardiac conditions. Long-term growth drivers include progress of its gene-regulation platform across multiple cardiac targets, the large unmet need in heart failure, and potential partnerships or label expansion that could support commercialization. Investors may find the company attractive because it appears positioned to deliver durable, first-in-class treatment approaches if key clinical and regulatory milestones are met.
Key risks include clinical trial setbacks and regulatory rejection, high cash burn with likely future financing needs, competition from alternative cardiac and gene therapies, and manufacturing and safety challenges inherent to gene-regulatory modalities.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.32
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.09
ROE
-66.69%
Net Debt
-33.26M
ROCE
-89.38%
Diluted EPS TTM
-1.65

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -123.67M -72.72M -38.40M -26.23M
Net income -123.66M -69.65M -38.31M -25.78M
Selling general administrative 31.08M 18.41M 7.81M 4.56M
Reconciled depreciation 6.47M 2.96M 2.48M 1.99M
Ebit -132.09M -75.77M -38.91M -27.71M
Ebitda -125.62M -72.81M -36.43M -25.72M
Depreciation and amortization 6.47M 2.96M 2.48M 1.99M
Non operating income net other 1.96M 0.09M - -
Operating income -125.62M -72.81M -38.91M -27.71M
Other operating expenses 125.62M 72.81M 38.91M 27.71M
Interest expense -0.00M 72.73M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M
Interest income 1.95M 0.11M 0.09M 0.45M
Net interest income 1.95M 0.11M 0.09M 0.45M
Income tax expense -0.00M -3.07M -0.09M -0.45M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 125.62M 72.81M 38.91M 27.71M
Total other income expense net 1.96M 0.09M 0.52M 1.48M
Net income from continuing ops -123.67M -72.72M -38.40M -26.23M
Net income applicable to common shares -123.67M -72.72M -38.40M -26.23M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 170.51M 278.94M 314.19M 148.16M 38.00M
Other current assets 6.94M 7.23M 4.06M 1.43M 1.12M
Total liab 31.09M 278.94M 35.66M 229.48M 81.74M
Total stockholder equity 139.42M 243.38M 278.53M -81.31M -43.74M
Other current liab 12.78M 10.66M 0.16M 4.02M 3.52M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -403.28M -279.20M -155.53M -82.81M -44.42M
Other liab - 0.23M 0.18M 3.68M 4.58M
Other assets 0.00M 4.79M 4.13M 1.01M 0.68M
Cash 45.68M 95.27M 38.13M 128.53M 23.87M
Total current liabilities 22.73M 24.25M 21.77M 5.04M 4.12M
Current deferred revenue - - 8.90M - -
Net debt -33.26M -80.17M -24.42M -128.53M -23.87M
Short term debt 4.32M 4.01M 1.99M - -
Short long term debt total 12.42M 15.10M 13.71M - -
Other stockholder equity 542.80M 522.95M 120.01M 1.50M 0.68M
Property plant equipment - 51.03M 43.02M 17.18M 9.57M
Total current assets 111.58M 193.75M 255.36M 129.96M 27.74M
Long term investments 0.00M 17.70M - - -
Net tangible assets - 243.38M 278.53M -81.31M -43.74M
Short term investments 58.96M 91.25M 213.17M 0.00M 2.75M
Accounts payable 5.63M 9.58M 10.72M 1.02M 0.60M
Accumulated other comprehensive income -0.11M -0.38M -0.14M - -
Common stock total equity - 0.01M 0.00M - -
Retained earnings total equity - -279.20M -155.53M - -
Non currrent assets other 4.99M 4.79M 4.13M 1.01M 0.68M
Non current assets total 58.93M 85.19M 58.83M 18.20M 10.26M
Capital lease obligations 12.42M 15.10M 15.70M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 104.27M -213.44M 2.75M -2.66M
Change to liabilities 6.01M 12.06M 0.14M 0.40M
Total cashflows from investing activities 83.65M -238.56M -7.01M -5.58M
Total cash from financing activities 77.77M 208.97M 147.27M 30.51M
Change to operating activities -2.51M -3.86M -0.38M -0.65M
Net income -123.67M -72.72M -38.40M -26.23M
Change in cash 56.99M -90.41M 104.81M 0.83M
Begin period cash flow 38.68M 129.08M 24.27M 23.44M
End period cash flow 95.67M 38.68M 129.08M 24.27M
Total cash from operating activities -104.42M -60.81M -35.45M -24.10M
Issuance of capital stock 77.39M 208.52M 147.24M 30.45M
Depreciation 6.47M 2.96M 2.48M 1.99M
Other cashflows from investing activities 0.01M 0.01M 0.01M 0.01M
Sale purchase of stock 77.77M -0.01M -0.00M -0.00M
Other cashflows from financing activities 0.38M 20.44M 147.27M 30.51M
Change to netincome 11.68M 3.01M 0.70M 0.40M
Capital expenditures 20.63M 25.12M 9.76M 2.93M
Cash flows other operating -4.61M -6.25M - -
Cash and cash equivalents changes 56.99M -90.41M - -
Change in working capital -0.85M 4.74M -0.23M -0.25M
Stock based compensation 11.47M 2.95M 0.74M 0.41M
Other non cash items 2.16M 1.06M -0.07M 0.06M
Free cash flow -125.05M -85.93M -45.21M -27.02M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
TNYA
Tenaya Therapeutics Inc		 0.04
13.97%		 0.36 - - - 2.41 -0.67
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Tenaya Therapeutics Inc

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

650 825 6990

https://www.tenayatherapeutics.com

140

Name Title Year Born
Mr. Faraz Ali M.B.A. CEO, Sec. & Director 1973
Dr. Deepak Srivastava M.D. Scientific Founder, Chairman of Scientific Advisory Board & Director 1967
Ms. Leone D. Patterson M.B.A. Chief Financial & Bus. Officer 1963
Dr. Whittemore G. Tingley M.D., PH.D. Chief Medical Officer 1968
Dr. Eric N. Olson Ph.D. Scientific Founder & Member of Scientific Advisory Board NA
Dr. Bruce R. Conklin Scientific Founder NA
Dr. Saptarsi Haldar M.D. Scientific Founder NA
Dr. Sheng Ding Scientific Founder NA
Dr. Benoit G. Bruneau Ph.D. Scientific Founder NA
Dr. Kee-Hong Kim Ph.D. Chief Technology Officer 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…